Publications


Consensus and Disagreement Between Experts and Community Practitioners Asked to Make Therapeutic Recommendations for Early Breast Cancer (EBC)


This poster, presented in December 2015 at the 38th San Antonio Breast Cancer Symposium meeting in San Antonio, Texas, highlights areas of consensus and disagreement among breast cancer experts and clinicians who used an innovative online treatment decision tool for neoadjuvant or adjuvant treatment of EBC.

Community physicians do not consistently align with expert recommendations for use of neoadjuvant or adjuvant therapy for many patients with EBC. For example, whereas experts did not recommend hormonal neoadjuvant therapy, 71% of tool users would use hormonal neoadjuvant therapy for HR+ EBC. Furthermore, not all tool users selected dual HER2-targeted neoadjuvant therapy even though all experts recommended this treatment for HER2+ EBC.

These data suggest that online tools providing customized, patient-specific expert advice may aid clinicians in optimizing treatment decisions for their patients with EBC.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?